Administration is fairly simple and easy: it is given as a twice-a-year subcutaneous injection by health care professionals. This ensures strict adherence, according to the company. The Medicines Company licensed inclisiran from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ), and under a 2013 agreement between the companies, Alnylam completed certain pre-clinical and Phase 1 studies. Subsequently, the Medicines Co. has assumed the responsibility for the further development and commercialization of the drug. It's a potentially disruptive player in the high-potential anti-PCSK9 lipid management market, valued at $23.6 billion in 2030, according to Gbola Amusa, head of health care research at Chardan. The analyst estimates that Inclisiran can capture $5.1 billion of the market.